Jointown Pharmaceutical Group (600998) Q3 2024 earnings summary

Executive summary

• Q3 revenue rose 3.57% year-over-year to ¥36.26 billion, with net profit attributable to shareholders up 1.64% to ¥488.55 million; Q3 marked a return to positive growth in both revenue and profit.

• Nine-month revenue was ¥113.43 billion, down 0.82% year-over-year; net profit attributable to shareholders was ¥1.70 billion, down 6.99%.

• Excluding the impact of last year's epidemic-driven demand, nine-month revenue grew 0.70% and net profit grew 10.16%.

• Key growth drivers included CSO brand promotion, pharmaceutical manufacturing (including OEM), and digital logistics and supply chain solutions.

Financial highlights

• Q3 operating cash flow was ¥543 million, up 93.36% year-over-year; nine-month operating cash flow was -¥2.66 billion, mainly due to slower receivables collection.

• Basic and diluted EPS for Q3 were ¥0.09, down 10% year-over-year; nine-month EPS was ¥0.34, down 5.56%.

• Total assets at quarter-end were ¥101.02 billion, up 8.87% from year-end; equity attributable to shareholders was ¥26.43 billion, up 10.20%.

• Gross margin for nine months was 7.93%, slightly up from 7.80% last year.

• Non-recurring gains for the nine months totaled ¥66.56 million, mainly from government grants and asset disposals.

Outlook and guidance

• Full-year operating cash flow is expected to turn positive, with intensified year-end receivables collection.

• Management expects continued improvement in operating results, driven by new product, new retail, and digital strategies.